News | December 31, 2025
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Subscribe To Our Newsletter & Stay Updated
